Transformative One-stop CRDMO Services for Next Generation Radiotherapy
· Empowering Radiopharmaceutical Discovery & CMC Development
· Accelerating Pre-clinical Evaluation and IIT Translational Validation
· Securing Clinical and Commercial Supply Chains
Transformative One-stop CRDMO Services for Next Generation Radiotherapy
· Empowering Radiopharmaceutical Discovery & CMC Development
· Accelerating Pre-clinical Evaluation and IIT Translational Validation
· Securing Clinical and Commercial Supply Chains
Who We Are
C-Ray Therapeutics is specialized in providing transformative end-to-end CRDMO services for innovative radiopharmaceuticals and Molecular Imaging CRO services for XDC biotechs. C-Ray offers the full range of services including CMC Development, Pre-clinical evaluation, IIT (Investigator Initiated Trial) translational validation with FIH data generation, IND Enabling, clinical supply and commercial scale cGMP production and supply with reliable logistics.
C-Ray has 28,000 square-meter, state-of-the-art, world class R&D and cGMP manufacturing facilities with the highest Class A Radiation Safety License allowing commercial scale operational volume of over 30+ radioisotopes. GLP-like preclinical study center has both small and big lab animal use permit with animal feeding and administration lab, animal PET/CT for imaging, gama counter and pathology lab for biodistribution and dosimetry analysis. The fully automated cGMP production lines of Lu-177, Ac-225, Cu-64 radio-labelled antibody, peptide and small molecules have been produced for IIT, IND enabling and clinical supply. More than 30 CRDMO projects have been delivered and are actively operated.
Production Facilities
World-class R&D and production facilities with Class A premises and global cGMP compliance
视频播放失败,请联系站点管理员!
Experience our Facilities
Our Partners
Radiopharmaceutical Innovation Ecosystem Alliance
As the global radiopharmaceutical market rapidly transforms oncology, neurology, and cardiovascular care, the industry faces critical challenges: limited isotope supply, fragmented R&D-to-commercialization workflows, and regulatory complexities.
To overcome these challenges, C-Ray formed the Radiopharmaceutical Innovation Alliance, powered by industry leaders: United Imaging, Perceptive, Quarkmed, GoBroad Healthcare and Grand Pharmaceutical Group Limited.